Session: SUN 88-129-Acromegaly & Prolactinoma
Poster Board SUN-128
Aim:The aim of the present study is to investigate plasma survivin levels in patients diagnosed with prolactinoma and demonstrate if it could be used a marker in diagnosis.
Materials and Methods: Prolactinoma patients were chosen among patients whose initial serum prolactin levels were greater than 250 ng/mL together with the presence of pituitary MRI showing adenoma. Other functional pituitary tumors were excluded by dynamic hormone tests in all patients. The group of patients consisted of 50 women, aged from 17 to 51 years. As a control group, 42 healthy women, aged from 22 to 45 years were included. Twenty patients were microprolactinoma, while five patients were macroprolactinoma. All patients received dopamine agonist therapy. Serum survivin levels were measured in the both groups.
Results: Survivin levels were significantly higher in patients with prolactinoma compared to controls [19 (10-39) pg/mL, 16 (8 -22), p = 0.042]. There was no difference between microadenoma and macroadenoma patients in survivin levels [17.5 (range, 10-38) pg/mL, 19 (range, 16-22) pg/mL; p = 0.879). Mean sizes of microadenomas and macroadenomas were 5 (range, 2-7) mm and 12 (range, 11-26) mm.
Conclusions: Higher survivin levels might be a molecular marker predicting the presence of prolactinoma. Large-scale research is needed to clarify its role in diagnosis of prolactinoma patients.
Nothing to Disclose: FDD, MN, EA, ZC, SG, HB, ZA, CC, YA
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters